Tenax Therapeutics Inc (TENX)

[RajunCajun]

OXYCYTE strange name change .... Aurum’s ABL-101 stroke technology is based on an oxygen carrying perflurocarbon (PFC), which is emulsified for intravenous use. This PFC not only acts as a stroke therapeutic, delivering oxygen beyond the stroke clot, but due to its effect on local oxygenation and in combination with MRI imaging, it is able to detect tissue under metabolic stress. Thus, ABL-101 has unique dual benefits of reducing brain cell death following acute stroke, while also providing important information guiding the use of further stroke treatments (Aurum preclinical data in press). Future trials will investigate the effect of ABL-101 on stroke-induced disability both in the overall stroke population, and in thrombectomy patients. The latter is an extremely interesting sub-population of stroke patients in which there have been highly promising recent clinical developments, and which may provide a more rapid route to market for novel stroke therapies.
Sound familiar, keep reading....
Same product obtained from Tenax Therapeutics. The name change is very convenient and will help investors forget, er, not recognize the PFC product across the pond in Clinical II trials this year.
Tenax virtually said OXCYTE is dead. This is what they told SEC.
“We have previously developed Oxycyte, a PFC-based oxygen carrier (…). As we have suspended the development of these PFC products (…), we do not expect that Oxycyte, Dermacyte or Wundecyte constitute a material portion of our business going forward.”

from TENAX (archived) pipeline / clinical trials / website :
Oxycyte
We are continuing development of Oxycyte through a collaborative agreement with Aurum Biosciences, Ltd. Our Oxycyte oxygen carrier product is a PFC-based oil in water emulsion, which is provided to the patient intravenously. The physical-chemical properties of PFCs enable our product to concentrate oxygen from the lungs and transport it through the body releasing it along the way. Over a period of days Oxycyte is gradually exhaled through the lungs during the normal process of respiration. Oxycyte requires no cross matching, so it is immediately available and compatible with all patients’ blood types. Oxycyte is provided as a sterile emulsion ready for intravenous administration. Because it contains no biological components, there is reduced risk of transmission of blood-borne viruses from human blood products.
https://web.archive.org/web/20170723172111/http://www.tenaxthera.com/pipeline/oxycyte/

So, investors you should reap the benefits from Aurum Biosciences Clinical Trials II JOINT VENTURE with Tenax reap of benefits. The venture keeps Tenax in the game along with you investors! They might hide it from the SEC, but not from you investors!
A new name in reincarnation. Do your homework PEOPLE.
All records have been removed from Tenax website. Tenax investors will reap the Arum Biosciences’ windfall after these trials??? How, with no product. Hidden in plain site. I owned stock when it was OXBO....